Smirnova Natalia F, Conlon Thomas M, Morrone Carmela, Dorfmuller Peter, Humbert Marc, Stathopoulos Georgios T, Umkehrer Stephan, Pfeiffer Franz, Yildirim Ali Ö, Eickelberg Oliver
Comprehensive Pneumology Center, Member of the German Center for Lung Research, Institute of Lung Biology and Disease, Helmholtz Zentrum München, Ludwig-Maximilians University Munich, Munich Germany.
Division of Respiratory Sciences and Critical Care Medicine, University of Colorado, Aurora, Colorado, USA.
JCI Insight. 2019 Feb 7;4(3):e123971. doi: 10.1172/jci.insight.123971.
Lung transplantation (LTx) is the only therapeutic option for many patients with chronic lung disease. However, long-term survival after LTx is severely compromised by chronic rejection (chronic lung allograft dysfunction [CLAD]), which affects 50% of recipients after 5 years. The underlying mechanisms for CLAD are poorly understood, largely due to a lack of clinically relevant animal models, but lymphocytic bronchiolitis is an early sign of CLAD. Here, we report that lymphocytic bronchiolitis occurs early in a long-term murine orthotopic LTx model, based on a single mismatch (grafts from HLA-A2:B6-knockin donors transplanted into B6 recipients). Lymphocytic bronchiolitis is followed by formation of B cell-dependent lymphoid follicles that induce adjacent bronchial epithelial cell dysfunction in a spatiotemporal fashion. B cell deficiency using recipient μMT-/- mice prevented intrapulmonary lymphoid follicle formation and lymphocytic bronchiolitis. Importantly, selective inhibition of the follicle-organizing receptor EBI2, using genetic deletion or pharmacologic inhibition, prevented functional and histological deterioration of mismatched lung grafts. In sum, we provided what we believe to be a mouse model of chronic rejection and lymphocytic bronchiolitis after LTx and identified intrapulmonary lymphoid follicle formation as a target for pharmacological intervention of long-term allograft dysfunction after LTx.
肺移植(LTx)是许多慢性肺病患者的唯一治疗选择。然而,肺移植后的长期存活受到慢性排斥反应(慢性肺移植功能障碍[CLAD])的严重影响,5年后50%的受者会受到影响。CLAD的潜在机制尚不清楚,主要是由于缺乏临床相关的动物模型,但淋巴细胞性细支气管炎是CLAD的早期迹象。在此,我们报告淋巴细胞性细支气管炎在长期小鼠原位肺移植模型中早期出现,该模型基于单个错配(将来自HLA-A2:B6基因敲入供体的移植物移植到B6受体中)出现。淋巴细胞性细支气管炎之后是B细胞依赖性淋巴滤泡的形成,其以时空方式诱导相邻支气管上皮细胞功能障碍。使用受体μMT-/-小鼠的B细胞缺陷可防止肺内淋巴滤泡形成和淋巴细胞性细支气管炎。重要的是,通过基因缺失或药物抑制选择性抑制滤泡组织受体EBI2,可防止错配肺移植物的功能和组织学恶化。总之,我们提供了我们认为的肺移植后慢性排斥反应和淋巴细胞性细支气管炎的小鼠模型,并确定肺内淋巴滤泡形成是肺移植后长期移植物功能障碍药物干预的靶点。